The global cardiac marker testing market size is expected to reach USD 9.73 billion by 2032, is expected to grow at a CAGR of 8.60% during the forecast period.
Cardiac marker testing plays a crucial role in diagnosing and managing cardiovascular diseases (CVDs), which remain one of the leading causes of mortality worldwide. Cardiac biomarkers are substances released into the bloodstream when the heart is damaged or stressed, enabling clinicians to assess the presence and severity of cardiac conditions. Common markers include troponin, creatine kinase-MB (CK-MB), myoglobin, and B-type natriuretic peptide (BNP). These tests have become essential tools for early diagnosis, risk stratification, and monitoring treatment efficacy.
The global cardiac marker testing market has witnessed significant growth over the past decade, driven by technological advancements, a rising prevalence of cardiovascular diseases, and increasing demand for point-of-care (POC) diagnostics.
𝐆𝐞𝐭 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐚𝐠𝐞𝐬 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
Competitive Insight
Some of the major players operating in the global cardiac marker testing market include
- Roche,
- Abbott Laboratories,
- Danaher Corporation,
- Siemens Healthineers,
- Becton Dickson,
- Bio-Rad Laboratories,
- Thermo Fisher Scientific,
- LSI Medience,
- Quidel Corporation,
- Randox Laboratories,
- PerkinElmer,
- Tosoh Corporation,
- Alfa Scientific Designs,
- Response Biomedical, &
- Creative Diagnostics.
Market’s Growth Drivers
Several factors are contributing to the robust growth of the cardiac marker testing market:
- Increasing Cardiovascular Disease Burden: The growing incidence of heart attacks, heart failure, and other CVDs due to sedentary lifestyles, unhealthy diets, and rising obesity rates is a major driver. According to the World Health Organization (WHO), CVDs account for nearly 32% of all global deaths.
- Technological Advancements: Innovations in biomarker assays, such as high-sensitivity troponin tests, have enhanced the accuracy and speed of diagnoses. The integration of artificial intelligence (AI) and machine learning in diagnostics is also creating new opportunities.
- Growing Demand for Point-of-Care Testing: POC testing devices offer rapid results and convenience, particularly in emergency settings. Their portability and user-friendly design are driving their adoption in hospitals, ambulances, and even at home.
- Aging Population: As the global population ages, the prevalence of age-related cardiovascular conditions is rising, further fueling demand for cardiac marker testing.
- Increased Awareness and Preventive Care: Public health campaigns and advancements in preventive medicine are encouraging regular screening for cardiac risks, driving market growth.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:
The research study includes segmental analysis that divides the market into distinct groups or segments based on common characteristics. With market segmentation, businesses can identify specific customer groups that are more likely to be interested in specific products or services. Also, it enables these businesses to focus their marketing efforts and resources more efficiently, leading to higher conversion rates and improved return on investment. Furthermore, segmentation analysis helps companies develop personalized products or services, which can result in increased customer loyalty and improved customer satisfaction.
Cardiac Marker Testing Market, Product Outlook (Revenue – USD Billion, 2019-2032)
- Reagents and Kits
- Instruments
Cardiac Marker Testing Market, Application Outlook (Revenue – USD Billion, 2019-2032)
- Laboratory Testing Facilities
- Point-Of-Care Testing Facilities
- Academic Institutions
Cardiac Marker Testing Market, Biomarker Type Outlook (Revenue – USD Billion, 2019-2032)
- Troponin I and T
- Creatine Kinase-MB (CK-MB)
- Natriuretic Peptide
- Myoglobin
- High-Sensitivity C-Reactive Protein
- Other Cardiac Biomarkers
Key Trends
The cardiac marker testing market is shaped by several key trends:
- High-Sensitivity Cardiac Biomarkers: High-sensitivity assays for troponin are setting new standards in diagnosing acute myocardial infarction (AMI). These tests enable earlier detection and better patient outcomes.
- Point-of-Care Testing Revolution: Portable devices equipped with advanced technologies are increasingly preferred in emergency and primary care settings. This trend aligns with the growing demand for decentralized healthcare solutions.
- Integration with Digital Health: Combining cardiac marker testing with wearable devices and digital platforms is emerging as a game-changer. These solutions provide continuous monitoring, enabling proactive management of cardiac health.
- Biomarker Discovery: Researchers are exploring new biomarkers, such as galectin-3 and growth differentiation factor-15 (GDF-15), to improve diagnostic precision and expand the range of detectable cardiac conditions.
- Focus on Emerging Markets: Rapid healthcare infrastructure development in Asia-Pacific, Latin America, and the Middle East is opening new opportunities for market expansion.
Research Scope
Research in the cardiac marker testing market encompasses various aspects, including:
- Novel Biomarker Identification: Discovering and validating new biomarkers to address unmet diagnostic needs.
- Technological Innovations: Developing next-generation testing platforms that offer higher sensitivity, specificity, and ease of use.
- Clinical Utility Studies: Evaluating the real-world effectiveness of cardiac biomarkers in improving patient outcomes.
- Cost-Effectiveness Analysis: Assessing the economic viability of implementing advanced biomarker tests in healthcare systems.
- Regulatory Frameworks: Understanding and navigating the regulatory pathways for biomarker assays across different regions.
Future Scope
The future of the cardiac marker testing market looks promising, with several developments on the horizon:
- Personalized Medicine: Advances in genomics and proteomics will enable more personalized approaches to cardiac care, using biomarker profiles tailored to individual patients.
- Expansion of POC Testing: The shift toward decentralized healthcare will drive innovations in POC testing, making it more accessible and affordable globally.
- AI-Driven Diagnostics: Artificial intelligence will play a pivotal role in interpreting cardiac marker data, identifying patterns, and predicting outcomes with greater accuracy.
- New Biomarker Applications: Emerging biomarkers will expand the diagnostic scope beyond traditional CVDs, addressing conditions such as cardiomyopathies and cardiac toxicity from cancer therapies.
- Global Market Penetration: Companies will increasingly target untapped markets in developing countries, leveraging collaborations and strategic partnerships.
Recent Developments
In January 2022, PocDoc, a leading digital health platform and personal diagnostics provider, announced the launch of a groundbreaking smartphone-based cardiovascular test. This innovative test, the first of its kind, is initially being offered to pharmacies, private healthcare providers, and NHS providers. The test covers the full five-marker lipid panel, and the company estimates that its technology could save the NHS millions of pounds annually by reducing staffing requirements.
In May 2022, Quidel Corporation introduced the “Triage Cardiac Panel,” an FDA-approved diagnostic tool designed for use in emergency departments (EDs). This panel aids in diagnosing myocardial infarction by measuring key biomarkers, including creatine kinase MB, myoglobin, and troponin I.
Rising incidence of cardiovascular diseases across the globe has paved the way for greater adoption of advanced cardiac marker testing devices or systems, as these devices help in early detection and diagnosis of several CVD diseases including myocardial infraction, heart attack, heart failure, and acute coronary syndrome, that are anticipated to boost the demand and growth of the global cardiac marker testing in the near future. For instance, as per statistics published by the WHO, cardiovascular diseases are leading cause of death across the globe with an accounting 17.9 million deaths, that represents about 32% of all global deaths.
More Trending Latest Reports By Polaris Market Research:
Breast Lesion Localization Market
Industrial Air Compressor Market